Telomere Lengths, Pulmonary Fibrosis and Telomerase (TERT) Mutations
Open accessThe DOI matches its Crossref record; 34 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Telomerase is an enzyme that catalyzes the addition of nucleotides on the ends of chromosomes. Rare loss of function mutations in the gene that encodes the protein component of telomerase (TERT) have been described in patients with idiopathic pulmonary fibrosis (IPF). Here we examine the telomere lengths and pulmonary fibrosis phenotype seen in multiple kindreds with heterozygous TERT mutations. METHODS AND FINDINGS: We have identified 134 individuals with heterozygous TERT mutations from 21 unrelated families. Available medical records, surgical lung biopsies and radiographs were evaluated retrospectively. Genomic DNA isolated from circulating leukocytes has been used to measure telomere lengths with a quantitative PCR assay. We find that telomere lengths of TERT mutation carriers decrease in an age-dependent manner and show progressive shortening with successive generations of mutation inheritance. Family members without TERT mutations have a shorter mean telomere length than normal, demonstrating epigenetic inheritance of shortened telomere lengths in the absence of an inherited TERT mutation. Pulmonary fibrosis is an age-dependent phenotype not seen in mutation carriers less than 40 years of age but found in 60% of men 60 years or older; its development is associated with environmental exposures including cigarette smoking. A radiographic CT pattern of usual interstitial pneumonia (UIP), which is consistent with a diagnosis of IPF, is seen in 74% of cases and a pathologic pattern of UIP is seen in 86% of surgical lung biopsies. Pulmonary fibrosis associated with TERT mutations is progressive and lethal with a mean survival of 3 years after diagnosis. Overall, TERT mutation carriers demonstrate reduced life expectancy, with a mean age of death of 58 and 67 years for males and females, respectively. CONCLUSIONS: A subset of pulmonary fibrosis, like dyskeratosis congenita, bone marrow failure, and liver disease, represents a "telomeropathy" caused by germline mutations in telomerase and characterized by short telomere lengths. Family members within kindreds who do not inherit the TERT mutation have shorter telomere lengths than controls, demonstrating epigenetic inheritance of a shortened parental telomere length set-point.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In IPF patients with telomerase mutations, the mean age of onset is 51 years, although IPF can manifest as late as the ninth decade of life70,71.”
From The telomere syndromes (2012) · cites this paper as [70]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, both dyskeratosis congenita and IPF patients are prone to developing haematological malignancies, commonly manifesting as myelodysplasia or acute myeloid leukaemia70,75,76.”
From The telomere syndromes (2012) · cites this paper as [70]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Specific Association of Human Telomerase Activity with Immortal Cells and Cancer
Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L. C., Coviello, G. M., Wright, W. E., Weinrich, S. L., & Shay, J. W. (1994) · Science · doi:10.1126/science.7605428 · Cited by 7,091 · cited 1×
“hTERT is highly expressed in germ cells, cells with proliferative potential and immortalized cancer cells[3,4,5].”
Background(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.2.ats01 · Cited by 4,196
Identification of a specific telomere terminal transferase activity in tetrahymena extracts
Greider, C. W., & Blackburn, E. H. (1985) · Cell · doi:10.1016/0092-8674(85)90170-9 · Cited by 3,400 · cited 1×
“The human enzyme consists of both a functional RNA (hTR) and a reverse transcriptase protein component (hTERT)[1,2].”
BackgroundThe RNA Component of Human Telomerase
Feng, J., Funk, W. D., Wang, S.-S., Weinrich, S. L., Avilion, A. A., Chiu, C.-P., Adams, R. R., Chang, E., Allsopp, R. C., Yu, J., et al. (1995) · Science · doi:10.1126/science.7544491 · Cited by 2,227 · cited 1×
“The human enzyme consists of both a functional RNA (hTR) and a reverse transcriptase protein component (hTERT)[1,2].”
BackgroundTelomere reduction in human colorectal carcinoma and with ageing
Hastie, N. D., Dempster, M., Dunlop, M. G., Thompson, A. M., Green, D. K., & Allshire, R. C. (1990) · Nature · doi:10.1038/346866a0 · Cited by 1,650 · cited 1×
“Evidence of this is seen by the progressive shortening of telomere lengths of human mononuclear leukocytes with age[6] and several diseases of inherited telomerase dysfunction[7].”
BackgroundTelomere length measurement by a novel monochrome multiplex quantitative PCR method
Cawthon, R. M. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn1027 · Cited by 1,410 · cited 1×
“Multiplexed quantitative polymerase chain reaction (PCR) determination of telomere lengths were performed on a RotorGene real-time PCR system (Qiagen) as described[21] with 0.”
MethodTelomerase Mutations in Families with Idiopathic Pulmonary Fibrosis
Armanios, M. Y., Chen, J. J.-L., Cogan, J. D., Alder, J. K., Ingersoll, R. G., Markin, C., Lawson, W. E., Xie, M., Vulto, I., Phillips, J. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066157 · Cited by 1,357 · cited 1×
“Heterozygous loss-offunction mutations in TERT have been found in up to 15% of kindreds with the familial pulmonary fibrosis[17,18] and in 1–3% of sporadic cases[19,20].”
BackgroundIncidence and Prevalence of Idiopathic Pulmonary Fibrosis
Raghu, G., Weycker, D., Edelsberg, J., Bradford, W. Z., & Oster, G. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200602-163oc · Cited by 1,310 · cited 1×
“However, unlike DKC, IPF is much more common with its prevalence increasing with age to 65 cases per 100,000 for those 75 years or older [16].”
BackgroundSelf-citationHeiss, N. S., Knight, S. W., Vulliamy, T. J., Klauck, S. M., Wiemann, S., Mason, P. J., Poustka, A., & Dokal, I. (1998) · Nature Genetics · doi:10.1038/ng0598-32 · Cited by 976 · cited 1×
“Most DKC patients have mutations in the X-linked DKC1 gene, which encodes dyskerin[8]; fewer patients have mutations in TERC, which encodes hTR[9].”
BackgroundThe RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita
Vulliamy, T., Marrone, A., Goldman, F., Dearlove, A., Bessler, M., Mason, P. J., & Dokal, I. (2001) · Nature · doi:10.1038/35096585 · Cited by 960 · cited 1×
“Most DKC patients have mutations in the X-linked DKC1 gene, which encodes dyskerin[8]; fewer patients have mutations in TERC, which encodes hTR[9].”
Background
Cited by
Items 101–200 of 376
Kozlitina, J., & Garcia, C. K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051046 · Cited by 74
“Telomere lengths of 466 additional samples were measured using the above protocol; we had previously measured telomere lengths of these samples using a Southern blot method (Terminal Restriction Fragment Length, TRFL) [15].”
BackgroundMethodSelf-citationPulmonary phenotypes associated with genetic variation in telomere-related genes
Hoffman, T. W., van Moorsel, C. H. M., Borie, R., & Crestani, B. (2018) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000475 · Cited by 70
The Spectrum of Hepatic Involvement in Patients With Telomere Disease
Kapuria, D., Yakov, G. B., Ortolano, R., Cho, M. H., Kalchiem‐Dekel, O., Takyar, V. K., Lingala, S., Gara, N., Tana, M. M.-S., Kim, Y. J., et al. (2019) · Hepatology · doi:10.1002/hep.30578 · Cited by 71
Cutting, C. C., Bowman, W. S., Đao, N. H., Pugashetti, J. V., Garcia, C. K., Oldham, J. M., & Newton, C. A. (2021) · CHEST Journal · doi:10.1016/j.chest.2021.01.026 · Cited by 70
Self-citationSenescence and tissue fibrosis: opportunities for therapeutic targeting
O’Reilly, S., Tsou, P., & Varga, J. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.05.012 · Cited by 72
Triallelic and epigenetic-like inheritance in human disorders of telomerase
Collopy, L. C., Walne, A. J., Cardoso, S., de la Fuente, J., Mohamed, M., Toriello, H., Tamary, H., Ling, A. J. Y. V., Lloyd, T., Kassam, R., et al. (2015) · Blood · doi:10.1182/blood-2015-03-633388 · Cited by 63
Sex and gender in interstitial lung diseases
Kawano-Dourado, L. B., Glassberg, M. K., Assayag, D., Borie, R., & Johannson, K. A. (2021) · European Respiratory Review · doi:10.1183/16000617.0105-2021 · Cited by 72
Cottin, V., Crestani, B., Cadranel, J. L., Cordier, J. F., Marchand-Adam, S., Prévot, G., Wallaert, B., Bergot, E., Camus, P., Dalphin, J., et al. (2017) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2017.07.017 · Cited by 67
Adegunsoye, A., Newton, C. A., Oldham, J. M., Ley, B., Lee, C. T., Linderholm, A., Chung, J. H., Garcia, N. M., Zhang, D., Vij, R., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37193-6 · Cited by 65
Self-citationIdiopathic Pulmonary Fibrosis: An Altered Fibroblast Proliferation Linked to Cancer Biology
Vancheri, C. (2012) · Proceedings of the American Thoracic Society · doi:10.1513/pats.201203-025aw · Cited by 61
A progression-free end-point for idiopathic pulmonary fibrosis trials: lessons from cancer
Vancheri, C., & du Bois, R. M. (2012) · European Respiratory Journal · doi:10.1183/09031936.00115112 · Cited by 63
The Role of Genetic Testing in Pulmonary Fibrosis
Newton, C. A., Oldham, J. M., Applegate, C. D., Carmichael, N. E., Powell, K. P., Dilling, D. F., Schmidt, S. L., Scholand, M. B., Armanios, M. Y., Garcia, C. K., et al. (2022) · CHEST Journal · doi:10.1016/j.chest.2022.03.023 · Cited by 68
Self-citationZhang, D., & Newton, C. A. (2021) · CHEST Journal · doi:10.1016/j.chest.2021.06.037 · Cited by 72
Rare and Common Variants in KIF15 Contribute to Genetic Risk of Idiopathic Pulmonary Fibrosis
Zhang, D., Povysil, G., Kobeissy, P. H., Li, Q., Wang, B., Amelotte, M., Jaouadi, H., Newton, C. A., Maher, T. M., Molyneaux, P. L., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202110-2439oc · Cited by 59
Self-citationTirelli, C., Pesenti, C., Miozzo, M. R., Mondoni, M., Fontana, L., & Centanni, S. (2022) · Diagnostics · doi:10.3390/diagnostics12123107 · Cited by 57
Genetic Interstitial Lung Disease
Devine, M., & Garcia, C. K. (2011) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2011.11.001 · Cited by 58
Self-citationCombined pulmonary fibrosis and emphysema
Papiris, S. A., Triantafillidou, C., Manali, E. D., Kolilekas, L., Baou, K., Kagouridis, K., & Bouros, D. E. (2013) · Expert Review of Respiratory Medicine · doi:10.1586/ers.12.80 · Cited by 57
Borie, R., Kannengiesser, C., Nathan, N., Tabèze, L., Pradère, P., & Crestani, B. (2014) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2014.07.017 · Cited by 58
Fibrosis: Lessons from OMICS analyses of the human lung
Yu, G., Ibarra, G. H., & Kaminski, N. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.03.014 · Cited by 52
“Shortened telomeres are found in the blood of patients with IPF as [13] and are predictive of worst outcome [120] before and after transplantation [121].”
BackgroundLiu, Y., Shi, Y., Liu, Y., Pan, X., & Zhang, K. (2018) · Acta Pharmacologica Sinica · doi:10.1038/s41401-018-0007-9 · Cited by 57
Ogura, T., Takigawa, N., Tomii, K., Kishi, K., Inoue, Y., Ichihara, E., Homma, S. A., Takahashi, K., Akamatsu, H., Ikeda, S., et al. (2019) · Respiratory Investigation · doi:10.1016/j.resinv.2019.06.001 · Cited by 54
The clinical and functional effects of TERT variants in myelodysplastic syndrome
Reilly, C. R., Myllymäki, M., Redd, R., Padmanaban, S., Karunakaran, D., Tesmer, V., Tsai, F. D., Gibson, C. J., Rana, H. Q., Zhong, L., et al. (2021) · Blood · doi:10.1182/blood.2021011075 · Cited by 51
Kass, D. J., Yu, G., Loh, K. S., Savir, A., Borczuk, A., Kahloon, R., Juan-Guardela, B., Deiuliis, G., Tedrow, J., Choi, J., et al. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.01.010 · Cited by 51
George, G., Rosas, I. O., Cui, Y., McKane, C. K., Hunninghake, G. M., Camp, P. C., Raby, B. A., Goldberg, H. J., & El‐Chemaly, S. (2014) · CHEST Journal · doi:10.1378/chest.14-0631 · Cited by 50
van der Meer, D., Hoekstra, P. J., van Donkelaar, M. M. J., Bralten, J., Oosterlaan, J., Heslenfeld, D. J., Faraone, S. V., Franke, B., Buitelaar, J. K., & Hartman, C. A. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.114 · Cited by 57
Evaluation and Management of Hematopoietic Failure in Dyskeratosis Congenita
Agarwal, S. (2018) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2018.04.003 · Cited by 52
Role of Cellular Senescence and NOX4-Mediated Oxidative Stress in Systemic Sclerosis Pathogenesis
Piera-Velázquez, S., & Jiménez, S. A. (2014) · Current Rheumatology Reports · doi:10.1007/s11926-014-0473-0 · Cited by 53
Translational research in pulmonary fibrosis
Mathai, S. K., & Schwartz, D. A. (2019) · Translational research · doi:10.1016/j.trsl.2019.02.001 · Cited by 53
Senescence in Pulmonary Fibrosis: Between Aging and Exposure
Venosa, A. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.606462 · Cited by 54
Zhang, D., Newton, C. A., Wang, B., Povysil, G., Noth, I., Martínez, F. J., Raghu, G., Goldstein, D. B., & Garcia, C. K. (2022) · European Respiratory Journal · doi:10.1183/13993003.00577-2022 · Cited by 55
Self-citationKLF4 regulates TERT expression in alveolar epithelial cells in pulmonary fibrosis
Wang, H., Xu, H., Lyu, W., Xu, Q., Fan, S., Chen, H., Wang, D., Chen, J., & Dai, J. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04886-7 · Cited by 50
Telomerase RNA processing: Implications for human health and disease
Nagpal, N., & Agarwal, S. (2020) · Stem Cells · doi:10.1002/stem.3270 · Cited by 48
Natural History of Pulmonary Fibrosis in Two Subjects With the Same Telomerase Mutation
El‐Chemaly, S., Ziegler, S. G., Calado, R. T., Wilson, K. A., Wu, H. P., Haughey, M., Peterson, N. R., Young, N. S., Gahl, W. A., Moss, J., et al. (2010) · CHEST Journal · doi:10.1378/chest.10-2048 · Cited by 48
Potential Role of Cellular Senescence in Asthma
Wang, Z.-N., Su, R., Yang, B.-Y., Yang, K., Yang, L., Yan, Y., & Chen, Z. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00059 · Cited by 51
Cellular and Molecular Mechanisms in Idiopathic Pulmonary Fibrosis
Zhang, Y., & Wang, J. (2023) · Advances in respiratory medicine · doi:10.3390/arm91010005 · Cited by 53
Hepatic manifestations of telomere biology disorders
Patnaik, M. M., Kamath, P. S., & Simonetto, D. A. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.05.006 · Cited by 46
“Scar-cinoma”: viewing the fibrotic lung mesenchymal cell in the context of cancer biology
Horowitz, J. C., Osterholzer, J. J., Marazioti, A., & Stathopoulos, G. T. (2016) · European Respiratory Journal · doi:10.1183/13993003.01201-2015 · Cited by 45
Gaysinskaya, V. A., Stanley, S. E., Adam, S. S., & Armanios, M. Y. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.07.025 · Cited by 43
Telomeres in Interstitial Lung Disease
Stock, C. J. W., & Renzoni, E. A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10071384 · Cited by 47
“The average age of death in ILD smokers with TERT or TERC mutations is 10 years earlier than in mutationcarrying non-smokers [35], and an association between smoking history and pulmonary fibrosis in TERT mutation carriers ≥40 years of age has been shown [14].”
BackgroundMaitra, M., Cano, C. A., & Garcia, C. K. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1217069110 · Cited by 46
“Rare loss-of-function mutations in TERT are found in ∼15% of all affected kindreds and are collectively the most common genetic abnormality found in these families (4).”
BackgroundInfluentialSelf-citationRetractedSex and Gender in Lung Disease and Sleep Disorders
Sodhi, A., Pisani, M. A., Glassberg, M. K., Bourjeily, G. R., & D’Ambrosio, C. M. (2022) · CHEST Journal · doi:10.1016/j.chest.2022.03.006 · Cited by 44
Nelson, A. S., Marsh, R. A., Myers, K. C., Davies, S. M., Jodele, S., O'Brien, T. A., & Mehta, P. A. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.01.026 · Cited by 41
“However, it does not alter other features of the disease, such as pulmonary fibrosis, liver cirrhosis and fibrosis, or proliferative retinopathy [3,9-16].”
BackgroundIdiopathic pulmonary fibrosis will increase the risk of lung cancer
Li, J., Ming, Y., Ping, L., Su, Z., Gao, P., & Jie, Z. (2014) · Chinese Medical Journal · doi:10.3760/cma.j.issn.0366-6999.20141346 · Cited by 44
“Also, patients with sporadic and familial IPF have other mutations related to carcinogenesis, such as telomere shortening and telomerase expression.(63) Additionally, hypermethylation of the Thy-1 promoter region causes reduced expression of glycoprotein Thy-1, which is normally expressed in lymphocytes and fibroblast…”
BackgroundTelomere Abnormalities in the Pathobiology of Idiopathic Pulmonary Fibrosis
Bilgili, H., Białas, A. J., Górski, P., & Piotrowski, W. J. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8081232 · Cited by 40
“observed that pulmonary fibrosis associated with TERT mutations was progressive, with reduced life expectancy [40].”
BackgroundInfluentialInsights from human genetic studies of lung and organ fibrosis
Garcia, C. K. (2018) · Journal of Clinical Investigation · doi:10.1172/jci93556 · Cited by 40
“Population-based and genetically defined at-risk cohorts demonstrate a higher penetrance of pulmonary fibrosis associated with smoking and various inhaled “fibrogenic” exposures (27, 115, 116).”
BackgroundSelf-citationChronic inflammation and lung fibrosis: pleotropic syndromes but limited distinct phenotypes
Gifford, A. H., Matsuoka, M., Ghoda, L. Y., Homer, R., & Enelow, R. I. (2012) · Mucosal Immunology · doi:10.1038/mi.2012.68 · Cited by 36
Gansner, J. M., & Rosas, I. O. (2013) · Translational research · doi:10.1016/j.trsl.2013.04.001 · Cited by 42
Clinical implications of telomere dysfunction in lung fibrosis
Molina‐Molina, M., & Borie, R. (2018) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000506 · Cited by 39
At the stem of youth and health
Beltrami, A. P., Cesselli, D., & Beltrami, C. A. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.10.005 · Cited by 39
Bennett, D., Mazzei, M. A., Squitieri, N. C., Bargagli, E., Refini, R. M., Fossi, A., Volterrani, L., & Rottoli, P. (2017) · Respiratory Medicine · doi:10.1016/j.rmed.2017.03.020 · Cited by 37
Whole exome sequencing analysis in severe chronic obstructive pulmonary disease
Qiao, D., Ameli, A., Prokopenko, D., Chen, H., Kho, A. T., Parker, M. M., Morrow, J. D., Hobbs, B. D., Liu, Y., Beaty, T. H., et al. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy269 · Cited by 37
Arias‐Salgado, E. G., Gálvez, E. H., Planas‐Cerezales, L., Pintado‐Berninches, L., Vallespín, E., Martínez, P., Carrillo, J., Iarriccio, L., Ruiz‐Llobet, A., Català, A., et al. (2019) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-019-1046-0 · Cited by 37
A Familial History of Pulmonary Fibrosis in Patients with Chronic Hypersensitivity Pneumonitis
Okamoto, T., Miyazaki, Y., Tomita, M., Tamaoka, M., & Inase, N. (2012) · Respiration · doi:10.1159/000338123 · Cited by 37
Idiopathic pulmonary fibrosis and the role of genetics in the era of precision medicine
Alonso-González, A., Tosco-Herrera, E., Molina‐Molina, M., & Flores, C. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1152211 · Cited by 46
Incorporating genetics into the identification and treatment of Idiopathic Pulmonary Fibrosis
Mathai, S. K., Yang, I. V., Schwarz, M. I., & Schwartz, D. A. (2015) · BMC Medicine · doi:10.1186/s12916-015-0434-0 · Cited by 37
“Patients carrying TERT mutations have a poor prognosis with reduced life expectancy [41].”
BackgroundEpigenetic Modifications in Hepatic Stellate Cells Contribute to Liver Fibrosis
Zhao, Q., Qin, C., Zhao, Z., Fan, Y., & Wang, K. (2012) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.229.35 · Cited by 38
“Regard ing the issue of inheritance, another investigation compared telomere length between normal people and “special” people, who have sibship with hepatopathy patients (Diaz de Leon et al. 2010).”
BackgroundGenetic cartography of longevity in humans and mice: Current landscape and horizons
Hook, M., Roy, S., Williams, E. G., Sleiman, M. S. B., Mozhui, K., Nelson, J. F., Lu, L., Auwerx, J. H., & Williams, R. W. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.01.026 · Cited by 37
Mesenchymal Stem Cell Therapy and Lung Diseases
Akram, K. M., Samad, S., Spiteri, M. A., & Forsyth, N. R. (2012) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_2012_140 · Cited by 36
“Unlike CF, to date, no specific genetic or acquired cause has been identified for IPF; however, mutation in the genes encoding for hTERT [6, 38, 123] and SP-C [120] Mesenchymal Stem Cell Therapy and Lung Diseases”
BackgroundCottin, V., Tomassetti, S., Valenzuela, C., Walsh, S. L. F., Antoniou, K. M., Bonella, F., Brown, K. K., Collard, H. R., Corte, T. J., Flaherty, K. R., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202111-2607pp · Cited by 37
Self-citationTargeted resequencing reveals genetic risks in patients with sporadic idiopathic pulmonary fibrosis
Deng, Y., Li, Z., Liu, J., Wang, Z., Cao, Y., Mou, Y., Fu, B., Mo, B., Wei, J., Cheng, Z., et al. (2018) · Human Mutation · doi:10.1002/humu.23566 · Cited by 32
Are leukocytes in asthmatic patients aging faster? A study of telomere length and disease severity
Kyoh, S., Venkatesan, N., Poon, A. H., Nishioka, M., Lin, T., Baglole, C. J., Eidelman, D. H., & Hamid, Q. A. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.02.010 · Cited by 32
Pulmonary Fibrosis and a TERT Founder Mutation With a Latency Period of 300 Years
van der Vis, J. J., van der Smagt, J. J., Hennekam, F. A. M., Grutters, J. C., & van Moorsel, C. H. M. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.03.069 · Cited by 32
Morphology of the Aging Lung on Computed Tomography
Copley, S. J. (2016) · Journal of Thoracic Imaging · doi:10.1097/rti.0000000000000211 · Cited by 31
HIV Infection Is Associated with Shortened Telomere Length in Ugandans with Suspected Tuberculosis
Auld, E., Lin, J., Chang, E. G., Byanyima, P., Ayakaka, I., Musisi, E., Worodria, W. O., Davis, J. L., Segal, M. R., Blackburn, E. H., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0163153 · Cited by 33
“diseases including pulmonary fibrosis, [25] and chronic obstructive pulmonary disease (COPD).”
BackgroundHolohan, B., Meyer, T. D., Batten, K. G., Mangino, M., Hunt, S. C., Bekaert, S., Buyzere, M. D., Rietzschel, E. R., Spector, T. D., Wright, W. E., et al. (2015) · Aging Cell · doi:10.1111/acel.12347 · Cited by 31
“…et al., 2010), and inheriting mutant telomerase alleles paternally is more detrimental to telomere length compared to the same alleles transmitted maternally (Diaz de Leon et al., 2010), although the parent-specific heritability of telomere length is still not fully determined (Eisenberg, 2014).”
BackgroundVenosa, A., Cowman, S. J., Katzen, J. B., Tomer, Y., Armstrong, B. S., Mulugeta, S., & Beers, M. F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.665818 · Cited by 33
Hecker, L., & Thannickal, V. J. (2011) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31821a9d66 · Cited by 33
Pulmonary fibrosis in non‐mutation carriers of families with short telomere syndrome gene mutations
van der Vis, J. J., van der Smagt, J. J., van Batenburg, A. A., Goldschmeding, R., van Es, H. W., Grutters, J. C., & van Moorsel, C. H. M. (2021) · Respirology · doi:10.1111/resp.14145 · Cited by 29
Klay, D., Grutters, J. C., van der Vis, J. J., Platenburg, M. G. J. P., Kelder, J. C., Tromp, E., & van Moorsel, C. H. M. (2022) · CHEST Journal · doi:10.1016/j.chest.2022.11.002 · Cited by 28
Evolving Genomic Approaches to Idiopathic Pulmonary Fibrosis: Moving Beyond Genes
Kass, D. J., & Kaminski, N. (2011) · Clinical and Translational Science · doi:10.1111/j.1752-8062.2011.00287.x · Cited by 29
Clinical Impact of Telomere Length Testing for Interstitial Lung Disease
Zhang, D., Eckhardt, C. M., McGroder, C. F., Benesh, S., Porcelli, J., Depender, C., Bogyo, K., Westrich, J. A., Thomas‐Wilson, A., Jobanputra, V., et al. (2024) · CHEST Journal · doi:10.1016/j.chest.2024.06.006 · Cited by 27
Self-citationNovel variants in Nordic patients referred for genetic testing of telomere-related disorders
Norberg, A., Rosén, A., Raaschou‐Jensen, K., Kjeldsen, L., Moilanen, J. S., Paulsson-Karlsson, Y., Baliakas, P., Lohi, O., Ahmed, A. B., Kittang, A. O., et al. (2018) · European Journal of Human Genetics · doi:10.1038/s41431-018-0112-8 · Cited by 27
Multiple Solid Organ Transplantation in Telomeropathy: Case Series and Literature Review
Lebeer, M., Wuyts, W. A., Cassiman, D. M., Laleman, W., Nevens, F., Pirenne, J., Monbaliu, D. R. L., Roskams, T., Verbeken, E. K., Neyrinck, A., et al. (2018) · Transplantation · doi:10.1097/tp.0000000000002198 · Cited by 28
Clinical Genetics in Interstitial Lung Disease
Newton, C. A., Molyneaux, P. L., & Oldham, J. M. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00116 · Cited by 29
Thalidomide interaction with inflammation in idiopathic pulmonary fibrosis
Dsouza, N. N., Alampady, V., Baby, K., Maity, S., Byregowda, B. H., & Nayak, Y. (2023) · Inflammopharmacology · doi:10.1007/s10787-023-01193-1 · Cited by 32
The oncogenic landscape of the idiopathic pulmonary fibrosis: a narrative review
Stella, G. M., D’Agnano, V., Piloni, D., Saracino, L., Lettieri, S., Mariani, F., Lancia, A., Bortolotto, C., Rinaldi, P., Falanga, F., et al. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-880 · Cited by 31
“The overall penetrance of pulmonary fibrosis in TERT mutation carriers is 40% in subjects with a mean age of 51 years (64-68).”
BackgroundThe world of rare interstitial lung diseases
Buschulte, K., Cottin, V., Wijsenbeek, M. S., Kreuter, M., & Diesler, R. (2023) · European Respiratory Review · doi:10.1183/16000617.0161-2022 · Cited by 27
Treatment and monitoring of hypersensitivity pneumonitis
Miyazaki, Y., Tsutsui, T., & Inase, N. (2016) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2016.1182426 · Cited by 28
“two chronic HP patients as telomerase reverse transcriptase mutation carriers, suggesting that patients with various forms of interstitial pneumonia, including HP, might have genetic susceptibility to pulmonary fibrosis [98].”
BackgroundFacts and promises on lung biomarkers in interstitial lung diseases
Campo, I., Zorzetto, M., & Bonella, F. (2015) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.2015.1062367 · Cited by 26
“In a study on 134 individuals with heterozygous TERT mutations from 21 unrelated families, the presence of an ILD was associated with increased age [155].”
BackgroundLee, C. T., Gandhi, S. A., Elmrayed, S. A., Barnes, H., Lorenzetti, D., Salisbury, M. L., Stewart, I. D., Barber, C. M., Peters, C., Feary, J. R., et al. (2025) · Thorax · doi:10.1136/thorax-2024-222306 · Cited by 25
Sidali, S., Borie, R., de Fontbrune, F. S., Husseini, K. E., Rautou, P., Lainey, É., Goria, O., Crestani, B., Cadranel, J. L., Cottin, V., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000667 · Cited by 26
“[11] Liver stiffness ≥ 20 kPa, FIB-4 score ≥ 3.25, and HVPG ≥ 10 mm Hg at baseline were correlated to poor survival.”
BackgroundInfluentialPersonalized Medicine: Applying ‘omics’ to Lung Fibrosis
Herazo‐Maya, J. D., & Kaminski, N. (2012) · Biomarkers in Medicine · doi:10.2217/bmm.12.38 · Cited by 25
Cellular senescence in normal and premature lung aging
Bartling, B. (2013) · Zeitschrift für Gerontologie und Geriatrie · doi:10.1007/s00391-013-0543-3 · Cited by 26
Mechanisms of nucleotide selection by telomerase
Schaich, M. A., Sanford, S. L., Welfer, G. A., Johnson, S. A., Khoang, T. H., Opresko, P. L., & Freudenthal, B. (2020) · eLife · doi:10.7554/elife.55438 · Cited by 24
Genetic architecture of human fibrotic diseases: disease risk and disease progression
Gardet, A., Zheng, T. S., & Viney, J. L. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00159 · Cited by 24
Demystifying pulmonary fibrosis
Jenkins, G. R. (2020) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00365.2020 · Cited by 24
“Interestingly, males with FPF caused by TERT mutations have a lower age of death than females (13).”
BackgroundCottin, V., Crestani, B., Cadranel, J. L., Cordier, J. F., Marchand-Adam, S., Prévot, G., Wallaert, B., Bergot, E., Camus, P., Dalphin, J., et al. (2017) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2017.07.018 · Cited by 25
“[51] Diaz de Leon A, Cronkhite JT, Katzenstein AL, et al.”
BackgroundSevere Asthma: Have we Made Progress?
Poon, A. H., & Hamid, Q. A. (2016) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201508-514mg · Cited by 22
Idiopathic pulmonary fibrosis a rare disease with severe bone fragility
Caffarelli, C., Gonnelli, S., Pitinca, M. D. T., Francolini, V., Fui, A., Bargagli, E., Refini, R. M., Bennett, D., Nuti, R., & Rottoli, P. (2016) · Internal and Emergency Medicine · doi:10.1007/s11739-016-1501-z · Cited by 22
Current Treatment Strategies for Non-Small-Cell Lung Cancer with Comorbid Interstitial Pneumonia
Ikeda, S., Kato, T., Kenmotsu, H., Sekine, A., Baba, T., & Ogura, T. (2021) · Cancers · doi:10.3390/cancers13163979 · Cited by 23
Budd, D. C., & Holmes, A. M. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.06.001 · Cited by 26
Differential telomerase expression in idiopathic pulmonary fibrosis and non-small cell lung cancer
Antoniou, K. M., Samara, K. D., Lasithiotaki, I., Margaritopoulos, G. A., Soufla, G., Lambiri, I., Giannarakis, I., Drositis, I., Spandidos, D. A., & Siafakas, N. M. (2013) · Oncology Reports · doi:10.3892/or.2013.2753 · Cited by 22
“expressed in germ cells, cells with proliferative potential and in immortalized cancer cells (9-11), although in most other cells, telomerase activity is restricted in humans (12).”
BackgroundAdult interstitial lung diseases and their epidemiology
Sésé, L., Khamis, W., Jeny, F., Uzunhan, Y., Duchemann, B., Valeyre, D., Annesi‐Maesano, I., & Nunès, H. (2020) · La Presse Médicale · doi:10.1016/j.lpm.2020.104023 · Cited by 29
Borie, R., Kannengiesser, C., & Crestani, B. (2012) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e328356b15c · Cited by 22
“%) are responsible for about 20% of all FIP.”
BackgroundInfluentialExtrahematopoietic manifestations of the short telomere syndromes
Schratz, K. E. (2020) · Hematology · doi:10.1182/hematology.2020000170 · Cited by 26
Giri, N., Ravichandran, S., Wang, Y., Gadalla, S. M., Alter, B. P., Fontana, J. R., & Savage, S. A. (2019) · ERJ Open Research · doi:10.1183/23120541.00209-2019 · Cited by 22
Xu, L., Bian, W., Gu, X., & Shen, C. (2017) · COPD Journal of Chronic Obstructive Pulmonary Disease · doi:10.1080/15412555.2017.1278753 · Cited by 19
Leukocyte telomere length as a diagnostic biomarker for anti-tuberculosis drug-induced liver injury
Udomsinprasert, W., Chanhom, N., Suvichapanich, S., Wattanapokayakit, S., Mahasirimongkol, S., Chantratita, W., & Jittikoon, J. (2020) · Scientific Reports · doi:10.1038/s41598-020-62635-2 · Cited by 19
Valenti, L. V. C., Dongiovanni, P., Maggioni, M., Motta, B. M., Rametta, R., Milano, M., Fargion, S. R., Reggiani, P., & Fracanzani, A. L. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.09.011 · Cited by 19
“As loss-of-function mutations in the telomerase (TERT) gene are responsible, in combination with environmental factors, for a significant proportion of cases of familial idiopathic pulmonary fibrosis [4,5], the patient was tested at the Department of Internal Medicine, University of Milan, and the c.”
Rasaei, R., Tyagi, A., Rasaei, S., Lee, S., Yang, S., Kim, K.-S., Ramakrishna, S., & Hong, S. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-03136-z · Cited by 18
“Genetic studies in familial and sporadic IPF patients have revealed an association between IPF susceptibility and telomerase-related genes [18], surfactant-associated genes [19, 20], mucin 5B gene, toll interacting protein (TOLLIP), and the signal peptide peptidase like 2C (SPPL2C) [21, 22].”
Background
Metadata
- Authors
- Diaz de Leon, A., Cronkhite, J. T., Katzenstein, A.-L. A., Godwin, J. D., Raghu, G., Glazer, C. S., Rosenblatt, R. L., Girod, C. E., Garrity, E. R., Xing, C., & Garcia, C. K.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- SUNY Upstate Medical University (US)
- University of Washington Medical Center (US)
- University of Chicago (US)
- Corresponding author
- Garcia, Christine Kim
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2010-05-19
- Volume
- 5
- Issue
- 5
- Pages
- e10680
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC2873288
- OpenAlex
- W2035774221
- Cited by
- 377
- References
- 35
- Citations by year
- 2026: 13 · 2025: 18 · 2024: 22 · 2023: 22 · 2022: 27 · 2021: 24 · 2020: 24 · 2019: 27 · 2018: 34 · 2017: 23 · 2016: 22 · 2015: 23 · 2014: 24 · 2013: 31 · 2012: 25
- FWCI
- 16.01
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Knowledge@UChicago (University of Chicago) (submittedVersion, cc-by-nc-nd)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Doris Duke Charitable Foundation
- American Heart Association
- National Institutes of Health
- National Heart, Lung, and Blood Institute (R01HL093096)
- National Center for Research Resources (K23RR020632)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Keywords
- telomere length, idiopathic pulmonary fibrosis, TERT mutation, telomerase, telomeropathies, epigenetic inheritance, usual interstitial pneumonia, cigarette smoking, dyskeratosis congenita, germline mutations, age-dependent phenotype, survival
- MeSH terms
- Adult, Aged, Aged, 80 and over, Family, Female, Heterozygote, Humans, Male, Middle Aged, Mutation, Pedigree, Phenotype, Pulmonary Fibrosis, Radiography, Respiratory Function Tests, Smoking, Telomere, Telomerase, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.